Report Highlights
The global excipients market was at $4.6 billion in 2010 and it is expected to reach at $4.9 billion in 2011. It is further anticipated to increase to $6.7 billion by 2016 at a compound annual growth rate (CAGR) of 6.5%.
SCOPE OF REPORT
Excipients in Pharmaceuticals offers coverage of the most important issues surrounding excipients: technological, regulatory, economic, and political issues, and so on.
Excluded from the study are ingredients for cosmetics, personal care, food, quasi-medical, unorthodox, alternative, home remedies, underground and/or illegal drugs, and veterinary drugs.
This report organizes information from diverse sources into sections entitled Summary, Overview, Technology, Industry Structure, and Company Profiles. The Summary encapsulates several key conclusions and includes a table of market findings. The Overview provides deep background information on the most important issues of the day, including the global supply chain crisis, QbD, and legislative prospects. The Technology section examines excipients by chemical compounds, functional uses, and delivery systems, and as finished products. The Industry Structure section discusses the market environment, strategies, influences, market shares, international aspects, and other related factors. The Company Profiles segment provides summaries of more than 120 companies that supply excipients or are relevant to the industry.
ANALYST CREDENTIALS
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of several previous BCC reports on various aspects of the pharmaceutical marketplace as well as analyses of major trends and the pharmaceutical regulatory environment.
Report Highlights
- Overall sales in the global excipients market were worth $4.1 billion in 2008, and increased to an estimated $4.3 billion in 2009. By 2014, it is projected to increase to $5.9 billion, for a 5-year compound annual growth rate (CAGR) of 6.3%.
- The largest segment of the market, organic chemicals, was valued at $3.8 billion in 2008; this is expected to increase to $4 billion in 2009, and is projected to reach $5.5 billion in 2014, for a 5-year CAGR of 6.4%.
- Sales in the USP (U.S. Pharmacopeia-grade) Water segment amounted to $79 million in 2008, increased to an estimated $84 million in 2009, and is projected to increase to $104 million in 2014, for a 5-year CAGR of 4.4%.
Report Highlights
-
The chemical compounds used to make excipients are valued at $4.3 billion market value for 2011, up from $3.5 billion in 2006. The dominance of USP water, particularly water for injection, skews the market volume and sets the pace for the anticipated 5.1% average annual market volume growth rate over the next five years.
-
Formulators will continue to use excipients to give their final drug products the necessary or desired functional use or properties. Vehicles, with an estimated 2011 market volume of 9.6 billion pounds, lead due to the large amount of USP water consumed.
-
Fillers follow with an estimated 849 million pounds of excipient chemical compounds being used in that functional category in five years. In terms of market value, the situation is reversed. Fillers come out on top, with an estimated 2011 market value of $1.2 billion, and vehicles drop to third place with $781 million, just below emollients at $816 million.
Report Highlights
-
In 2001, the global market for pharmaceutical (drug) inert ingredients was an estimated 7.25 billion pounds, of which water, accounted for about 77% of the total.
-
Overall growth of all drug inert ingredients is the order of 5% per year.
-
Injectables, essentially all Rx, constitute the single largest dosage form of excipients used in 2001 with almost 1.9 billion Kgs.
-
Nonaqueous biological use will grow to 563 million Kgs by 2007, an average annual growth rate (AAGR) of 4.5%.
Related Reports
Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets
The global pharmaceutical contract manufacturing and contract research organizations revenue reached $196.5 billion in 2010, and it will further grow to $217.9 billion in 2011. The market is projected to reach $360.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 10.6%.
Markets for Emerging Pharmaceutical Technologies
As a segment, therapeutic vaccines recorded $19.3 billion in 2010, a figure that is expected to grow to $31.9 billion by 2015, demonstrating a compound annual growth rate (CAGR) of 10.6%.
Anti-Counterfeiting Packaging Technologies in the Global Pharmaceutical and Food Industries
Global sales of anti-counterfeiting packaging technologies to the drug and food industries amounted to $59 billion in 2009 and are projected to reach $74.2 billion in 2015, a compound annual growth rate (CAGR) of 3% from 2010 to 2015. North America is projected to account for 59.8% of global sales, making it the largest market for anti-counterfeiting packaging technologies in 2015.
Process Analytical Technologies for Pharmaceuticals: Global Markets
The global market for process analytical technology (PAT) instrumentation was valued at nearly $195 million in 2010. This market is expected to increase by a 7.4% compound annual growth rate (CAGR) to reach an estimated $279 million in 2015.
Recent Reports
Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets
The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More